Reported resultsCompany-reported
What was reported
BOSTON, Mass – May 7, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
What the evidence supports
Ginkgo Bioworks published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $19 million | “•First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%.” Mentions: revenue |
| $38 million | “•First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%.” Mentions: revenue |
| $7 million | “As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement.” Mentions: revenue, cash |
| $31 million | “Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%.” Mentions: revenue, cash |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineGinkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous LabU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Press release lead paragraphBOSTON, Mass – May 7, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Amount stated in press release•First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Amount stated in press releaseAs previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Amount stated in press releaseExcluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.